
Get tickets
ASCO 2026 Annual Meeting
on ASCO
PANCREATIC SURVIVAL
2×
TUMOUR RESPONSE
26/83
CASES/YR BY 2050
35.3M
WORKFORCE GAP
100M
The 2026 American Society of Clinical Oncology annual meeting in Chicago delivered a stack of clinical trial results that, taken together, represent a genuine shift in oncology's toolkit. The headline: several new drugs operating through novel mechanisms — not incremental refinements of existing therapies — showed measurable survival and tumour-response gains in cancers that have historically resisted treatment. The conference drew 40,000 health professionals across more than 200 sessions and 2,700 poster presentations.
Extraction Map
The most striking result was daraxonrasib, a daily pill for metastatic pancreatic cancer tested in 500 patients by the Dana-Farber Cancer Institute. It doubled median survival to 13.2 months versus 6.6–6.7 months for chemotherapy, with fewer side effects. Pancreatic cancer has been essentially untreatable at the metastatic stage for decades. Dr Rachna Shroff of the University of Arizona Cancer Center, not involved in the study, called the results "landscape-changing" and said she wept when she first read them. A second class of results centred on drugs that strip tumour cells of immune evasion. GRWD5769, an experimental oral tablet tested at the Christie NHS Foundation Trust in Manchester across 83 patients in the UK, France, Spain and Australia, removed "invisibility cloaks" from cancer cells so that the immunotherapy cemiplimab could detect and destroy them. Tumours shrank in 26 of 83 patients; 15 achieved reductions of at least 30% — across cervical, bladder, liver, bowel, lung and head and neck cancers where immunotherapy had already failed. A parallel drug, ivonescimab, combined with chemotherapy extended lung cancer survival by 15%. A third, ozekibart, showed promise in bowel cancer by mimicking a natural protein to trigger cancer cell death. For patients with an incurable blood cancer, mezigdomide added to existing therapies more than doubled progression-free survival in multiple myeloma. Equally significant were the de-escalation results. The Optima trial, led by University College London and spanning 4,000 breast cancer patients across six countries, demonstrated that a genomic test can identify women who can safely skip chemotherapy entirely and be treated with hormone therapy alone. Durvalumab added to chemo and radiotherapy spared bladder cancer patients from surgery while reducing recurrence risk. These findings point toward personalised medicine that removes unnecessary suffering — a different kind of advance than new drugs, but no less valuable. Not everything worked. Galleri, the multi-cancer early detection blood test billed as oncology's holy grail, failed its primary endpoint in a 142,000-patient NHS trial. It did not shift diagnoses to earlier, more treatable stages. "The trial flopped," one delegate said. "Clear and simple." This matters because early detection has been positioned as the systemic answer to rising cancer incidence — and the leading candidate just failed at scale. The structural challenge underneath all of this is demographic. Global cancer diagnoses are projected to rise from 20 million per year to 35.3 million by 2050 — 100,000 per day — driven by a 21% increase in incidence from 165 to 200 per 100,000 people. The world faces a shortage of 100 million healthcare workers by 2050 to cope with this volume. Early-onset cancer cases rose 79% from 1.82 million in 1990 to 3.26 million in 2019, with deaths among under-50s up 27%. Two studies presented at ASCO linked poor sleep to the rise in younger diagnoses. Dr Peter Kingham of Memorial Sloan Kettering framed it bluntly: "Cancer is fundamentally a disease of ageing. This demographic shift is not a failure — it reflects remarkable progress in global health, but it demands an equally ambitious response." The tension at the core of ASCO 2026 is between genuine therapeutic innovation and systemic capacity to deploy it. New drugs with novel mechanisms are arriving — oral tablets that unmask tumours, pills that double survival in previously untreatable cancers, genomic tests that eliminate unnecessary chemotherapy. But the delivery infrastructure is not scaling with the disease burden. Access to clinical trials remains "appallingly low" per Pancreatic Cancer UK. The workforce gap is measured in the hundreds of millions. The drugs are generative; the system they must flow through is fragile.
Worth reading?
RECOMMENDED
Score
72
/100
Generative — novel drug mechanisms (immune unmasking, targeted protein degradation, genomic de-escalation) expand the therapeutic frontier rather than redistributing existing treatments, but generative potential is throttled by workforce and access bottlenecks.
What Is GRIN?
GRIN stands for Generativity, Resilience, Innovation efficiency, and Novelty openness. These four dimensions capture the essential characteristics of any memetic intelligence — whether a nation, a corporation, a religion, or a movement.
About GRINGenerativity
5/5
Resilience
3/5
Efficiency
3/5
Novelty
4/5
Extractive
2/5
Inverted
Does this create new capability or just redistribute existing value?
Strongly generative. At least four novel mechanisms of action — immune unmasking, protein degradation, genomic de-escalation, targeted cell death — create capabilities that did not exist before. Daraxonrasib doubled pancreatic survival from a near-zero baseline.
Verified Facts (12)
40,000 health professionals attended the 2026 ASCO annual meeting in Chicago
GRWD5769 alongside cemiplimab: tumours shrank in 26 of 83 patients; 15 had tumour reductions of at least 30%
Daraxonrasib: 500-patient trial, median survival 13.2 months vs 6.6–6.7 months for chemotherapy
Optima trial: 4,000 patients across UK, Norway, Sweden, Australia, New Zealand and Thailand
Galleri: 142,000 NHS patients; failed to meet primary endpoint of reducing late-stage diagnoses
Cancer incidence projected to rise from 165 per 100,000 in 2025 to 200 per 100,000 in 2050
Global diagnoses projected to rise from 20 million to 35.3 million per year by 2050
100 million healthcare staff shortage expected by 2050
Early-onset cancer cases increased from 1.82m in 1990 to 3.26m in 2019
Cancer deaths among under-50s rose by 27%
Mezigdomide: patients lived more than twice as long without cancer progressing
Ivonescimab combined with chemotherapy helped lung cancer patients live 15% longer on average
More latest news
Read all